The 'Block 5' rocket is the first Falcon 9 rocket that can theoretically be reused 10 times without any maintenance, and up to 100 times with just minor servicing. If SpaceX can pull off seven successful 'Block 5' launches, the company could get clearance from NASA to do manned missions, says Will Goodman, managing editor of Rockets Are Cool.
For the full interview, [click here](https://cheddar.com/videos/spacexs-falcon-from-the-block-2).
A U.S. appeals court has ruled against major oil companies in lawsuits brought by California cities and counties seeking damages for climate change.
While the choice to get out this Memorial Day is ultimately a calculated personal risk, many are hoping to find a way to see friends and family for the first time in months.
From Wall Street to Silicon Valley, these are the top stories that moved markets and had investors, business leaders, and entrepreneurs talking this week on Cheddar.
Backyard grilling is an American institution. But have you ever wondered where it came from? You might be surprised to learn that the history of your weekend barbecue twists and turns back through the earliest years of America’s past.
Apple and Google on Wednesday released long-awaited smartphone technology to automatically notify people if they might have been exposed to the coronavirus.
U.S. health officials have quietly released more reopening guidance that was created more than a month ago but initially shelved.
Dr. Leana Wen, an emergency physician, explained the potential risks of taking hydroxychloroquine, and how President Trump needs to change his rhetoric for the sake of public health.
Scientists say if the world returns to normal pollution levels, the temporary reductions will amount to a drop in the ocean when it comes to curbing global warming.
President Donald Trump said Monday that he is taking a malaria drug to lessen symptoms should he get the new coronavirus, even though the drug is unproven for fighting COVID-19.
Cambridge-based Moderna Inc. said Monday that its vaccine triggered immune responses in eight healthy, middle-aged volunteers.
